Sutro Biopharma Current Ratio 2017-2021 | STRO
For a detailed definition, formula and example for Current Ratio, check out our new background page here.
Sutro Biopharma current ratio from 2017 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Sutro Biopharma Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2021-06-30 |
$0.28B |
$0.03B |
10.63 |
| 2021-03-31 |
$0.27B |
$0.02B |
11.74 |
| 2020-12-31 |
$0.38B |
$0.03B |
12.78 |
| 2020-09-30 |
$0.29B |
$0.03B |
9.77 |
| 2020-06-30 |
$0.26B |
$0.04B |
7.29 |
| 2020-03-31 |
$0.13B |
$0.03B |
3.98 |
| 2019-12-31 |
$0.13B |
$0.03B |
3.90 |
| 2019-09-30 |
$0.14B |
$0.04B |
3.78 |
| 2019-06-30 |
$0.16B |
$0.04B |
4.49 |
| 2019-03-31 |
$0.18B |
$0.03B |
5.67 |
| 2018-12-31 |
$0.21B |
$0.04B |
5.76 |
| 2018-09-30 |
$0.13B |
$0.04B |
3.45 |
| 2018-06-30 |
$0.00B |
|
0.00 |
| 2018-03-31 |
$0.00B |
|
0.00 |
| 2017-12-31 |
$0.00B |
|
0.00 |
| 2017-09-30 |
$0.00B |
|
0.00 |
| 2016-12-31 |
$0.05B |
$0.05B |
0.99 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.877B |
$0.043B |
|
Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California.
|
